603392 万泰生物
已收盘 09-30 15:00:00
资讯
新帖
简况
万泰生物（603392）9月28日主力资金净买入513.44万元
证券之星 · 09-29
万泰生物（603392）9月28日主力资金净买入513.44万元
万泰生物：二十价肺炎球菌多糖结合疫苗产业化项目相关费用已计入往期财报
证券之星 · 09-24
万泰生物：二十价肺炎球菌多糖结合疫苗产业化项目相关费用已计入往期财报
万泰生物：公司仪器确认销售收入的时点为客户验收，已发货未验收的仪器计入发出商品
证券之星 · 09-24
万泰生物：公司仪器确认销售收入的时点为客户验收，已发货未验收的仪器计入发出商品
万泰生物：公司经营一切正常
证券之星 · 09-24
万泰生物：公司经营一切正常
万泰生物：二价HPV疫苗已在泰国、印度尼西亚、柬埔寨、缅甸等国家获得市场准入
证券之星 · 09-24
万泰生物：二价HPV疫苗已在泰国、印度尼西亚、柬埔寨、缅甸等国家获得市场准入
万泰生物（603392）披露关于终止部分募投项目并变更募集资金用途的议案，9月23日股价上涨2.71%
证券之星 · 09-23
万泰生物（603392）披露关于终止部分募投项目并变更募集资金用途的议案，9月23日股价上涨2.71%
万泰生物：2026年第一次临时股东会决议公告
证券日报网 · 09-23
万泰生物：2026年第一次临时股东会决议公告
万泰生物：公司高价肺炎球菌多糖结合疫苗按计划推进中
证券之星 · 09-17
万泰生物：公司高价肺炎球菌多糖结合疫苗按计划推进中
万泰生物：公司始终恪守诚信经营原则
证券之星 · 09-17
万泰生物：公司始终恪守诚信经营原则
万泰生物：在信息披露中需遵守监管要求
证券之星 · 09-17
万泰生物：在信息披露中需遵守监管要求
万泰生物：公司聚焦于体外诊断试剂和预防产品的业务领域
证券之星 · 09-17
万泰生物：公司聚焦于体外诊断试剂和预防产品的业务领域
万泰生物：九价 HPV 疫苗与二价 HPV 疫苗的市场环境、商业化基础不同
证券之星 · 09-17
万泰生物：九价 HPV 疫苗与二价 HPV 疫苗的市场环境、商业化基础不同
每周股票复盘：万泰生物（603392）拟变更肺炎疫苗项目募投资金用途
证券之星 · 09-13
每周股票复盘：万泰生物（603392）拟变更肺炎疫苗项目募投资金用途
万泰生物最新公告：实控人钟睒睒捐赠股份完成过户持股比例降至15.10%
证券之星 · 09-04
万泰生物最新公告：实控人钟睒睒捐赠股份完成过户持股比例降至15.10%
每周股票复盘：万泰生物（603392）实控人拟捐3300万股公司股份
证券之星 · 08-30
每周股票复盘：万泰生物（603392）实控人拟捐3300万股公司股份
8月26日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
证券之星 · 08-26
8月26日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股
万泰生物：公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场
证券之星 · 08-26
万泰生物：公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场
万泰生物（603392）披露实际控制人无偿捐赠部分公司股份公告，8月25日股价上涨0.04%
证券之星 · 08-25
万泰生物（603392）披露实际控制人无偿捐赠部分公司股份公告，8月25日股价上涨0.04%
万泰生物：实控人钟睒睒捐赠3300万股公司股份
格隆汇 · 08-25
万泰生物：实控人钟睒睒捐赠3300万股公司股份
8月24日万泰生物跌8.17%，疫苗ETF国泰基金重仓该股
证券之星 · 08-24
8月24日万泰生物跌8.17%，疫苗ETF国泰基金重仓该股
加载更多
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":27.34,"timestamp":1790751600000,"preClose":26.48,"halted":0,"volume":8986653,"delay":0,"changeRate":0.0325,"floatShares":1264000000,"shares":1264000000,"eps":-0.3026,"marketStatus":"已收盘","change":0.86,"latestTime":"09-30 15:00:00","open":26.6,"high":27.5,"low":26.44,"amount":245000000,"amplitude":0.04,"askPrice":27.35,"askSize":124,"bidPrice":27.34,"bidSize":78,"shortable":0,"etf":0,"ttmEps":-0.3026,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":26.48,"symbolType":"stock","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":29.13,"lowLimit":23.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1264392804,"isCdr":false,"pbRate":2.95,"roa":"--","roe":"--","epsLYR":-0.31,"committee":-0.399848,"marketValue":34568000000,"turnoverRate":0.0071,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","floatMarketCap":34568000000},"requestUrl":"/m/hq/s/603392","defaultTab":"news","newsList":[{"id":"2671138266","title":"万泰生物（603392）9月28日主力资金净买入513.44万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2671138266","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671138266?lang=zh_cn&edition=full","pubTime":"2026-09-29 08:22","pubTimestamp":1790641367,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月28日收盘，万泰生物报收于26.69元，上涨1.18%，换手率0.42%，成交量5.27万手，成交额1.39亿元。近5日资金流向一览见下表：万泰生物融资融券信息显示，融资方面，当日融资买入1115.13万元，融资偿还1074.31万元，融资净买入40.82万元，连续3日净买入累计570.77万元。万泰生物主营业务：体外诊断试剂、体外诊断仪器与疫苗的研发、生产及销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092900007107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","09633","LU1981816686.USD","BK0239","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464393","title":"万泰生物：二十价肺炎球菌多糖结合疫苗产业化项目相关费用已计入往期财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669464393?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:24","pubTimestamp":1790245450,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：二十价肺炎球菌多糖结合疫苗产业化项目终止后，给合作方的费用以及临床费用是否已经在往期财报中已经体现，后续无需计提？万泰生物回复：您好！公司二十价肺炎球菌多糖结合疫苗产业化项目涉及的合作方款项及临床试验相关费用，均在实际发生时严格按照《企业会计准则》相关规定计入对应会计期间的当期费用，已完整体现在公司往期各期财报中，后续无需就该项目相关合作款项及临床试验费用进行额外计提。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","159646","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669464392","title":"万泰生物：公司仪器确认销售收入的时点为客户验收，已发货未验收的仪器计入发出商品","url":"https://stock-news.laohu8.com/highlight/detail?id=2669464392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669464392?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:24","pubTimestamp":1790245449,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，请问从2024年底开始，财报中存货分类部分，多了一个“发出商品”的分类统计项目，请问该项目是用来做什么的？目前该项目中主要是那类商品？万泰生物回复：您好！公司仪器确认销售收入的时点为客户验收，已发货未验收的仪器计入发出商品。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032231.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK0239","09633","LU1981816686.USD","BK1589","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669046108","title":"万泰生物：公司经营一切正常","url":"https://stock-news.laohu8.com/highlight/detail?id=2669046108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669046108?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:21","pubTimestamp":1790245265,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问万泰是不是废了？二级市场的股价怎么跌跌不休？万泰生物回复：您好！理解您对股价持续下跌的焦虑，二级市场股价变动受诸多因素影响。目前公司经营一切正常，疫苗、诊断等业务稳步推进，各项研发与市场拓展工作有序开展。管理层将持续深耕主业、提质增效，夯实长期价值。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032147.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1589","BK0239","09633","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669646140","title":"万泰生物：二价HPV疫苗已在泰国、印度尼西亚、柬埔寨、缅甸等国家获得市场准入","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646140","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669646140?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:18","pubTimestamp":1790245094,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好：请问贵司的HPV疫苗在东盟国家内的准入情况如何。 东盟总人口超过6亿，且具备良好的购买能力，HPV疫苗出口该地区可以实现社会效益和商业效益。万泰生物回复：您好！公司高度重视东盟国家市场的布局与拓展。目前，二价HPV疫苗已在泰国、印度尼西亚、柬埔寨、缅甸等国家获得市场准入；九价HPV疫苗已获得泰国上市许可。在技术合作方面，公司已与泰国合作伙伴完成九价HPV疫苗技术转移。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400032083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","BK1589","LU1981816686.USD","09633","603392","159646","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669548109","title":"万泰生物（603392）披露关于终止部分募投项目并变更募集资金用途的议案，9月23日股价上涨2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669548109","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669548109?lang=zh_cn&edition=full","pubTime":"2026-09-23 22:14","pubTimestamp":1790172854,"startTime":"0","endTime":"0","summary":"截至2026年9月23日收盘，万泰生物报收于26.93元，较前一交易日上涨2.71%，最新总市值为340.5亿元。该股当日开盘26.19元，最高27.3元，最低26.06元，成交额达2.3亿元，换手率为0.68%。公告显示，公司于2026年9月23日召开2026年第一次临时股东会，审议通过《关于终止部分募投项目并变更募集资金用途的议案》，表决结果为同意948,485,661股，占出席会议有表决权股份的99.9497%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300040745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","BK1589","BK1200","603392","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669481772","title":"万泰生物：2026年第一次临时股东会决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2669481772","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669481772?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:38","pubTimestamp":1790167080,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月23日，万泰生物发布公告称，公司于2026年9月23日召开2026年第一次临时股东会，审议通过《关于终止部分募投项目并变更募集资金用途的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-23/doc-inisvqcx5322244.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-23/doc-inisvqcx5322244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","LU1981816686.USD","09633","BK1589","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668310966","title":"万泰生物：公司高价肺炎球菌多糖结合疫苗按计划推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2668310966","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668310966?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:15","pubTimestamp":1789640127,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月17日在投资者关系平台上答复投资者关心的问题。投资者提问：后续要推进的：高价肺炎球菌多糖结合疫苗项目，目前是否有后选疫苗存在？万泰生物回复：您好！公司高价肺炎球菌多糖结合疫苗按计划推进中。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","BK0239","LU1981816686.USD","159646","09633","BK1200","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668966326","title":"万泰生物：公司始终恪守诚信经营原则","url":"https://stock-news.laohu8.com/highlight/detail?id=2668966326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668966326?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:15","pubTimestamp":1789640126,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)09月17日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，你们的董事长邱先生，不是热衷于做慈善工作吗？那么，一个心怀慈悲的人，就更应该带动团队诚实守信的公布九价疫苗的销售进度与收入情况。万泰生物回复：您好！公司董事长及管理层高度重视社会责任与公益事业，践行企业担当；同时公司始终恪守诚信经营原则，严格按照证券法及上交所信息披露规则履行信息披露义务，保障全体投资者公平获取公司经营信息。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1589","BK0239","BK1200","09633","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668396637","title":"万泰生物：在信息披露中需遵守监管要求","url":"https://stock-news.laohu8.com/highlight/detail?id=2668396637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668396637?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:15","pubTimestamp":1789640125,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物09月17日在投资者关系平台上答复投资者关心的问题。请转告邱董及管理层。还不如前董秘余涛回复的一个批次15万到30万的实在，坦率，有价值。感谢您参加本次业绩说明会并直言反馈。在信息披露中，公司需要遵守监管要求，兼顾全体投资者信息公平与商业秘密保护，部分细分数据存在披露限制。公司将在合规前提下持续优化业绩沟通方式，提升沟通实效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1589","BK0239","BK1200","09633","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668663219","title":"万泰生物：公司聚焦于体外诊断试剂和预防产品的业务领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2668663219","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668663219?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:15","pubTimestamp":1789640124,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物09月17日在投资者关系平台上答复投资者关心的问题。另外关于养生堂的治疗性板块纳入万泰生物的紧迫性公司高层是否考虑过？公司与养生堂对生物医药领域的业务范围进行了界定划分：公司从事以疾病诊断、疾病预防为目的的产品的研发及产业化，养生堂从事以疾病治疗为目的的产品的研发及产业化。万泰生物聚焦于体外诊断试剂和预防产品的业务领域，治疗性创新药物属于养生堂集团的业务范围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030525.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1589","BK0239","09633","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668457965","title":"万泰生物：九价 HPV 疫苗与二价 HPV 疫苗的市场环境、商业化基础不同","url":"https://stock-news.laohu8.com/highlight/detail?id=2668457965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668457965?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:06","pubTimestamp":1789639573,"startTime":"0","endTime":"0","summary":"九价 HPV 疫苗与二价 HPV 疫苗的市场环境、商业化基础不同，不宜直接对比。九价 HPV 疫苗上市后，各省准入、渠道建设、市场教育均需要一定周期，新品上市阶段在准入、推广、团队建设方面投入较高，存在阶段性经营压力，是创新疫苗商业化过程中的常见情况。不同疫苗的目标市场、竞争格局存在差异，成长周期各不相同。公司后续会持续拓展海内外市场、优化渠道运营，稳步提升九价HPV疫苗市场销量与品牌影响力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700030343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK1589","BK1200","603392","LU1981816686.USD","BK0239","09633"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667171507","title":"每周股票复盘：万泰生物（603392）拟变更肺炎疫苗项目募投资金用途","url":"https://stock-news.laohu8.com/highlight/detail?id=2667171507","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667171507?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:19","pubTimestamp":1789237150,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，万泰生物报收于26.28元，较上周的27.67元下跌5.02%。本周，万泰生物9月10日盘中最高价报28.28元。本周关注点公司公告汇总：万泰生物拟终止二十价肺炎疫苗项目，将45,514.25万元募集资金变更用于高价肺炎球菌疫苗项目。公司公告汇总万泰生物第六届董事会第二十次会议于2026年9月7日召开，审议通过《关于终止部分募投项目并变更募集资金用途的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000573.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","603392","LU1981816686.USD","159646","BK0239","09633","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664352063","title":"万泰生物最新公告：实控人钟睒睒捐赠股份完成过户持股比例降至15.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664352063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664352063?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:10","pubTimestamp":1788516610,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，公司实际控制人钟睒睒向福建省翔安创新实验室科技发展基金会无偿捐赠其直接持有的3300万股无限售条件流通股，占公司总股本的2.61%，已完成过户登记手续。本次权益变动后，钟睒睒直接持股比例由17.71%降至15.10%，其与一致行动人养生堂有限公司合计持股比例由73.53%降至70.92%。本次权益变动不触及要约收购，不会导致公司控股股东及实际控制人发生变化。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090400032695.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1200","BK1589","09633","LU1981816686.USD","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663101380","title":"每周股票复盘：万泰生物（603392）实控人拟捐3300万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2663101380","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663101380?lang=zh_cn&edition=full","pubTime":"2026-08-30 03:08","pubTimestamp":1788030493,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，万泰生物报收于30.37元，较上周的30.59元下跌0.72%。本周，万泰生物8月27日盘中最高价报32.44元。万泰生物当前最新总市值384.0亿元，在医疗器械板块市值排名4/129，在两市A股市值排名528/5211。本次捐赠后，钟睒睒先生及其一致行动人合计持股比例由73.53%降至70.92%，不会导致公司控制权变化，不影响公司治理结构及持续经营。受赠方承诺受让股份后6个月内不减持，未来减持将与钟睒睒先生合并计算减持额度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1589","BK0239","BK1200","09633","LU1981816686.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662679647","title":"8月26日万泰生物涨10.00%，疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2662679647","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662679647?lang=zh_cn&edition=full","pubTime":"2026-08-26 16:32","pubTimestamp":1787733154,"startTime":"0","endTime":"0","summary":"证券之星消息，8月26日万泰生物涨10.00%，收盘报30.91元，换手率0.64%，成交量8.11万手，成交额2.45亿元。融资融券方面近5日融资净流出256.48万，融资余额减少；融券净流出100.0，融券余额减少。重仓万泰生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600036586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","159643","603392","BK0239","BK1589","LU1981816686.USD","BK1200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662793748","title":"万泰生物：公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2662793748","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662793748?lang=zh_cn&edition=full","pubTime":"2026-08-26 15:33","pubTimestamp":1787729615,"startTime":"0","endTime":"0","summary":"证券之星消息，万泰生物(603392)08月26日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好、请问目前国内的万泰HPV9价疫苗是否有供不应求的情况？万泰生物回复：您好！公司九价HPV疫苗生产正常运行，可持续、稳定且充足地供应市场。感谢您对公司的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600030000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","BK1200","09633","BK0239","LU1981816686.USD","603392","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662775874","title":"万泰生物（603392）披露实际控制人无偿捐赠部分公司股份公告，8月25日股价上涨0.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662775874","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662775874?lang=zh_cn&edition=full","pubTime":"2026-08-25 22:25","pubTimestamp":1787667953,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘，万泰生物报收于28.1元，较前一交易日上涨0.04%，最新总市值为355.29亿元。近日，万泰生物发布《关于实际控制人无偿捐赠部分公司股份的公告》。公告显示，公司实际控制人钟睒睒先生拟向福建省翔安创新实验室科技发展基金会无偿捐赠其直接持有的公司33,000,000股无限售条件流通股，占公司总股本的2.61%。受赠方承诺受让股份后6个月内不减持，未来减持将与钟睒睒先生合并计算减持额度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500050851.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK1200","09633","603392","BK0239","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662778082","title":"万泰生物：实控人钟睒睒捐赠3300万股公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2662778082","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662778082?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:12","pubTimestamp":1787649121,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","603392"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661212682","title":"8月24日万泰生物跌8.17%，疫苗ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661212682","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661212682?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:31","pubTimestamp":1787560281,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日万泰生物跌8.17%，收盘报28.09元，换手率1.11%，成交量14.07万手，成交额4.11亿元。重仓万泰生物的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为国泰基金的疫苗ETF国泰。疫苗ETF国泰目前规模为1.4亿元，最新净值0.5822，较上一交易日下跌3.63%，近一年下跌11.36%。疫苗ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159643","09633","LU1981816686.USD","BK0239","BK1589","603392","BK1200"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791022813824,"stockEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":-0.0569},{"period":"3month","weight":-0.0284},{"period":"6month","weight":-0.2915},{"period":"1year","weight":-0.5165},{"period":"ytd","weight":-0.3916}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42923人(较上一季度增加2.61%)","perCapita":"29457股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126439万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}